GlassScriptPhysician profile
Rhonda D Mace
NPI 1538261714
$637.65
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $101 · 2021: $70.04 · 2022: $28.03.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $194.82 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $150.43 | 2019-2020 | |
| Grifols USA, LLC | $52.63 | 2019-2020 | |
| Novo Nordisk INC | $51.75 | 2019 | |
| Amgen INC. | $50.28 | 2019-2020 | |
| Astellas Pharma US INC | $27.35 | 2019-2020 | |
| Amarin Pharma, INC. | $26.94 | 2020-2021 | |
| Eisai INC. | $20.68 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.23 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.61 | 2020 | |
| Glaxosmithkline, LLC. | $12.36 | 2019 | |
| Abbvie INC. | $11.65 | 2022 | |
| Allergan, INC. | $10.92 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhonda Mace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.